In this episode, Jamie E. Chaft, MD, provides her expert perspective on new data from WCLC 2020 in early-stage NSCLC, with topics including:

• Updated results from ADAURA on HRQoL and DFS outcomes with or without postoperative chemotherapy after adjuvant osimertinib
• An analysis of the ongoing ITACA study of personalizing chemotherapy based on biomarkers of drug resistance
• FDG PET/CT adaptive radiotherapy in RTOG 1106
• The TALENT study in Taiwan screening nonsmokers for lung cancer

Presenter:

Jamie E. Chaft, MD
Associate Attending Physician
Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
New York, New York

Content supported by educational grants from Amgen; Bristol-Myers Squibb; Ipsen Biopharmaceuticals; Janssen Pharmaceutica NV; Jazz Pharmaceuticals; Regeneron Pharmaceuticals, Inc. & Sanofi Genzyme; and Takeda Oncology.

Link to full program, including a downloadable highlights slideset, and ClinicalThought commentaries:
http://bit.ly/2NzE6X6

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.